World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
57
Citations
16986
World Ranking
4279
National Ranking
1936

Michael J. Pontecorvo publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Michael J. Pontecorvo sits on this spectrum.

38–47 publications: 18 scientists 48–57 publications: 79 scientists 58–67 publications: 193 scientists 68–77 publications: 323 scientists 78–87 publications: 406 scientists 88–97 publications: 452 scientists 98–107 publications: 539 scientists 108–117 publications: 505 scientists 118–127 publications: 522 scientists 128–137 publications: 469 scientists 138–147 publications: 456 scientists 148–157 publications: 459 scientists 158–167 publications: 397 scientists 168–177 publications: 383 scientists 178–187 publications: 350 scientists 188–197 publications: 302 scientists 198–207 publications: 306 scientists 208–217 publications: 262 scientists 218–227 publications: 242 scientists 228–237 publications: 220 scientists 238–247 publications: 203 scientists 248–257 publications: 174 scientists 258–267 publications: 176 scientists 268–277 publications: 175 scientists 278–287 publications: 125 scientists 288–297 publications: 116 scientists 298–307 publications: 127 scientists 308–317 publications: 128 scientists 318–327 publications: 99 scientists 328–337 publications: 89 scientists 338–347 publications: 78 scientists 348–357 publications: 96 scientists 358–367 publications: 66 scientists 368–377 publications: 59 scientists 378–387 publications: 65 scientists 388–397 publications: 54 scientists 398–407 publications: 48 scientists 408–417 publications: 49 scientists 418–427 publications: 34 scientists 428–437 publications: 31 scientists 438–447 publications: 30 scientists 448–457 publications: 31 scientists 458–467 publications: 36 scientists 468–477 publications: 40 scientists 478–487 publications: 35 scientists 488–497 publications: 30 scientists 498–507 publications: 23 scientists 508–517 publications: 26 scientists 518–527 publications: 20 scientists 528–537 publications: 23 scientists 538–547 publications: 20 scientists 548–557 publications: 20 scientists 558–567 publications: 17 scientists 568–577 publications: 14 scientists 578–587 publications: 20 scientists 588–597 publications: 20 scientists 598–607 publications: 19 scientists 608–617 publications: 18 scientists 618–627 publications: 17 scientists 628–637 publications: 11 scientists 638–647 publications: 11 scientists 648–657 publications: 11 scientists 658–667 publications: 8 scientists 668–677 publications: 7 scientists 678–687 publications: 11 scientists 688–697 publications: 10 scientists 698–707 publications: 4 scientists 708–717 publications: 6 scientists 718–727 publications: 5 scientists 728–737 publications: 5 scientists 738–747 publications: 9 scientists 748–757 publications: 9 scientists 758–767 publications: 3 scientists 768–777 publications: 7 scientists 778–787 publications: 7 scientists 788–797 publications: 6 scientists 798–807 publications: 2 scientists 808–817 publications: 2 scientists 818–827 publications: 7 scientists 828–837 publications: 0 scientists 838–847 publications: 9 scientists 848–857 publications: 3 scientists 858–867 publications: 1 scientists 868–877 publications: 3 scientists 878–886 publications: 6 scientists 887+ publications: 100 scientists
38 publications 887+

This scientist: 201 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 887 publications or more.

Michael J. Pontecorvo D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. Pontecorvo sits on this spectrum.

30–31 D-Index: 42 scientists 32–33 D-Index: 172 scientists 34–35 D-Index: 296 scientists 36–37 D-Index: 435 scientists 38–39 D-Index: 459 scientists 40–41 D-Index: 456 scientists 42–43 D-Index: 467 scientists 44–45 D-Index: 478 scientists 46–47 D-Index: 512 scientists 48–49 D-Index: 435 scientists 50–51 D-Index: 425 scientists 52–53 D-Index: 418 scientists 54–55 D-Index: 392 scientists 56–57 D-Index: 357 scientists 58–59 D-Index: 334 scientists 60–61 D-Index: 328 scientists 62–63 D-Index: 260 scientists 64–65 D-Index: 278 scientists 66–67 D-Index: 239 scientists 68–69 D-Index: 250 scientists 70–71 D-Index: 210 scientists 72–73 D-Index: 200 scientists 74–75 D-Index: 189 scientists 76–77 D-Index: 170 scientists 78–79 D-Index: 146 scientists 80–81 D-Index: 113 scientists 82–83 D-Index: 126 scientists 84–85 D-Index: 100 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 99 scientists 90–91 D-Index: 84 scientists 92–93 D-Index: 85 scientists 94–95 D-Index: 72 scientists 96–97 D-Index: 76 scientists 98–99 D-Index: 45 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 43 scientists 104–105 D-Index: 32 scientists 106–107 D-Index: 45 scientists 108–109 D-Index: 50 scientists 110–111 D-Index: 32 scientists 112–113 D-Index: 39 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 27 scientists 120–121 D-Index: 19 scientists 122–123 D-Index: 23 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 16 scientists 128–129 D-Index: 24 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 21 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 14 scientists 138–139 D-Index: 15 scientists 140–141 D-Index: 10 scientists 142–143 D-Index: 10 scientists 144–145 D-Index: 13 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 8 scientists 150–151 D-Index: 6 scientists 152–153 D-Index: 6 scientists 154–155 D-Index: 7 scientists 156–157 D-Index: 7 scientists 158–159 D-Index: 10 scientists 160–161 D-Index: 4 scientists 162 D-Index: 8 scientists 163+ D-Index: 100 scientists
30 D-Index 163+

This scientist: 57 D-Index — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 163 D-Index or more.

Overview

Michael J. Pontecorvo is affiliated with Eli Lilly in the United States and focuses on research in the medical field, particularly within dementia and cognitive impairment. Their work is concentrated on Alzheimer's disease research and treatments, with significant contributions to functional brain connectivity studies and medical imaging techniques. The scientist's expertise spans psychiatry and mental health, physiology, radiology including nuclear medicine and imaging, cognitive neuroscience, and neurology.

Their recent scientific publications include the following:

  • Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease, 2022, JAMA Neurology
  • Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease, 2022, Brain
  • Four distinct trajectories of tau deposition identified in Alzheimer's disease, 2021, Nature Medicine
  • Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease, 2021, JAMA Neurology
  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes, 2020, JAMA Neurology

Frequent coauthors of Michael J. Pontecorvo include:

  • Oskar Hansson
  • Rik Ossenkoppele
  • Michael D. Devous
  • Ruben Smith
  • Sergey Shcherbinin

The scientist's research is frequently published in the following venues:

  • Alzheimer's & Dementia
  • JAMA Neurology
  • Alzheimer's Research & Therapy
  • European Journal of Nuclear Medicine and Molecular Imaging
  • Brain

Main fields of study emphasize medicine, with detailed subfields including psychiatry and mental health, physiology, radiology and nuclear medicine imaging, cognitive neuroscience, and neurology.

Core topics in the work of Michael J. Pontecorvo comprise dementia and cognitive impairment research, Alzheimer's disease research and treatments, functional brain connectivity studies, medical imaging techniques and applications, advanced neuroimaging techniques, neurological disease mechanisms and treatments, as well as proteins such as S100 and annexins.

Best Publications

  • Use of Florbetapir-PET for Imaging β-Amyloid Pathology

    Christopher M. Clark;Julie A. Schneider;Barry J. Bedell;Thomas G. Beach

  • The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

    William E. Klunk;William E. Klunk;Robert A. Koeppe;Julie C. Price;Tammie L. Benzinger;Tammie L. Benzinger

  • In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

    Dean F. Wong;Paul B. Rosenberg;Yun Zhou;Anil Kumar

  • Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

    Christopher M Clark;Michael J Pontecorvo;Thomas G Beach;Barry J Bedell

  • Four distinct trajectories of tau deposition identified in Alzheimer’s disease

    Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  • Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

    Unknown

  • The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions

    Raymond T. Bartus;Reginald L. Dean;Michael J. Pontecorvo;Charles Flicker

  • Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

    Susan M. Landau;Susan M. Landau;Susan M. Landau;Christopher Breault;Abhinay D. Joshi;Michael Pontecorvo

  • Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

    Abhinay D. Joshi;Michael J. Pontecorvo;Chrisopher M. Clark;Alan P. Carpenter

  • Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

    Eric R. Siemers;Karen L. Sundell;Christopher Carlson;Michael Case

  • Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

    Susan M. Landau;Susan M. Landau;Ming Lu;Abhinay D. Joshi;Michael Pontecorvo

  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

    Adam S Fleisher;Michael J Pontecorvo;Michael D Devous;Ming Lu

  • Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

    Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Auttawut Roontiva

  • Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

    Michael J. Pontecorvo;Michael D. Devous;Michael Navitsky;Ming Lu

  • Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

    S. M. Landau;S. M. Landau;B. A. Thomas;L. Thurfjell;M. Schmidt

  • Selective memory loss following nucleus basalis lesions: long term behavioral recovery despite persistent cholinergic deficiencies.

    Raymond T. Bartus;Raymond T. Bartus;Charles Flicker;Reginald L. Dean;Michael Pontecorvo

  • Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

    Rik Ossenkoppele;Rik Ossenkoppele;Ruben Smith;Niklas Mattsson-Carlgren;Colin Groot

  • Individual differences in aging: Behavioral and neurobiological correlates

    Alicja L. Markowska;William S. Stone;Donald K. Ingram;Jay Reynolds

  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study

    P. Murali Doraiswamy;Reisa A. Sperling;R. Edward Coleman;Keith A. Johnson

  • Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.

    Keith A. Johnson;Reisa A. Sperling;Christopher M. Gidicsin;Jeremy S. Carmasin

  • Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease

    Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Napatkamon Ayutyanont

  • Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

    P M Doraiswamy;R A Sperling;K Johnson;E M Reiman

  • Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

    Jeffrey L. Cummings;Kate Zhong;Jefferson W. Kinney;Chelcie Heaney

Frequent Co-Authors

Michael D. Devous
Michael D. Devous Avid Radiopharmaceuticals
Andrew Siderowf
Andrew Siderowf University of Pennsylvania
Adam S. Fleisher
Adam S. Fleisher Avid Radiopharmaceuticals
Mark A. Mintun
Mark A. Mintun University of Pennsylvania
Christopher M. Clark
Christopher M. Clark University of Pennsylvania
Eric M. Reiman
Eric M. Reiman Arizona State University
Marwan N. Sabbagh
Marwan N. Sabbagh Lou Ruvo Brain Institute
Keith A. Johnson
Keith A. Johnson Harvard University
P. Murali Doraiswamy
P. Murali Doraiswamy Duke University
Reisa A. Sperling
Reisa A. Sperling Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Michael J. Pontecorvo

Trending Scientists

Recently Published Articles